Xometry stock price target maintained at $55 by RBC Capital

RBC Capital reiterated a Sector Perform rating on Xometry with a $55 price target and expects the company to beat consensus again when it reports Q1 earnings on May 7. The firm cited generally positive manufacturing macro data, 25.87% revenue growth over the last 12 months to $686.63 million, and expectations for a 10th consecutive revenue beat. Xometry’s shares have gained 93.2% over the past year, though InvestingPro flags the stock as overvalued versus fair value.

Analysis

The setup is less about a single beat and more about Xometry’s ability to turn a still-lukewarm industrial backdrop into operating leverage. If the company can keep compounding revenue while proving it can inch toward durable profitability, the market will likely re-rate the name on “quality of growth” rather than just topline momentum. That matters because the stock has already priced in a lot of execution; the next leg higher depends on margin inflection and guidance credibility, not another incremental revenue beat.

The key second-order effect is competitive: marketplaces with fragmented supplier networks tend to win share when procurement teams stay cautious, because buyers are looking for speed, flexibility, and quote efficiency without committing to fixed capacity. If macro conditions remain merely neutral, Xometry can still gain share from smaller, less digitized job shops that struggle with lead generation and utilization. The risk is that if manufacturing softens even modestly, revenue growth can remain intact for a quarter or two while take rates and unit economics quietly deteriorate.

Consensus may be underestimating how much of the valuation story is now tied to earnings quality rather than growth alone. A company that is already trading rich needs two things simultaneously: sustained outperformance and evidence that CAC payback, gross margin, or contribution margin are improving faster than expected. If the quarter shows only a top-line beat without better profitability, the stock could de-rate despite good headline numbers because investors will question whether the business is simply buying growth.

Catalyst-wise, the next 2-6 weeks matter more than the next 12 months: the print and guide will likely determine whether this remains a momentum story or becomes a multiple-expansion story. The cleanest contrarian read is that the setup is asymmetrically better on a pullback into earnings than chasing strength ahead of it, because expectations have been ratcheted up by prior beats and favorable commentary. A disappointment on guidance would likely hit harder than a small revenue miss, since the market is already looking for profitability inflection.

Key Decisions for Investors

• Do not chase XMTR ahead of earnings; prefer to wait for a post-print reaction. If the stock sells off 8-12% on a clean beat with raised guidance, initiate a starter long for a 1-3 month trade targeting a 15-20% rebound on multiple re-rating.
• If holding XMTR, consider a covered call into the event to monetize elevated expectations. Use a near-dated strike roughly 10-15% above spot to cap upside only if the print is merely in-line; this improves risk/reward if guidance is the true swing factor.
• For more aggressive exposure, buy a small call spread in XMTR into the May 7 catalyst. Favor a 1-2 month tenor and structure it for roughly 2:1 payoff if the market awards profitability progress and forward revenue acceleration.
• Pair trade: long XMTR / short a broader industrial cyclicals proxy if you want to isolate company-specific execution. The thesis is that Xometry can outperform even without a major macro re-acceleration, but the short should be sized modestly because macro weakness would hurt both legs.
• If the report shows only revenue strength with no margin progress, fade the move on strength rather than averaging up. That scenario likely limits upside to a modest beat-and-raise premium and could leave the stock vulnerable to a 10%+ de-rating over the following 2-4 weeks.